Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Relatlimab in Metastatic Melanoma
NCT03743766Phase 2Completed
- Start
- Mar 2019
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab, nivolumab in melanoma. Started Mar 2019; status: completed.
02
Drugs
relatlimabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03743766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743766.